The Clinical Study of Dexmedetomidine and Esketamine Combined Infusion Undergoing Modified Radical Mastectomy
Condition: Dexmedetomidine, Esketamine, Postoperative Pain and Recovery Quality
MeSH terms: Pain, Postoperative
Study type: Interventional

Summary: 
      BACKGROUND: Some studies have revealed that intravenous dexmedetomidine and esketamine
      alleviated postoperative pain and improve the quality of recovery after surgery. The
      investigators investigated whether co-administration dexmedetomidine and esketamine could
      better alleviated postoperative pain and improve the the quality of recovery after modified
      radical mastectomy.

      METHODS: One hundred and thirty-five women with elective modified radical mastectomy were
      randomly divided into 3 groups: Patients in group D received dexmedetomidine (0.5 µg/kg over
      10 min before the induction of anesthesia), and then dexmedetomidine was infused at a rate of
      0.4 μg/kg/h until 20 min before the end of operation. Patients in group DE1 received a bolus
      infusion of dexmedetomidine (0.5 µg/kg) and esketamine (0.5 mg/kg)over 10 min before the
      induction of anesthesia, and then dexmedetomidine were infused at a rate of 0.4 µg/kg/h and 2
      µg/kg/min until 20 min before the end of operation, respectively. Patients in group DE2
      received received a bolus infusion of dexmedetomidine (0.5 µg/kg) and esketamine (0.5
      mg/kg)over 10 min before the induction of anesthesia, and then dexmedetomidine were infused
      at a rate of 0.4 µg/kg/h and 4 µg/kg/min until 20 min before the end of operation,
      respectively. Primary outcome was the quality of recovery (QoR-15) at 1 day after sugery and
      3 day after sugery. The secondary outcomes included perioperative remifentanil consumption,
      postoperative VAS pain scores, side effects such as the incidence of postoperative nausea,
      vomiting and bradycardia, hallucination, nightmare, as well as postoperative rescue
      analgesics and anti-emetics, recovery time, and extubation time.
    


Intervention name(s): Dexmedetomidine infusion; Co-administration dexmedetomidine and low-dose esketamine infusion; Co-administration dexmedetomidine and high-dose esketamine infusion
Intervention type(s): Drug; Drug; Drug
Intervention description(s): Patients received dexmedetomidine (0.5 µg/kg over 10 min before the induction of anesthesia), and then dexmedetomidine was infused at a rate of 0.4 μg/kg/h until 20 min before the end of operation; Patients received a bolus infusion of dexmedetomidine (0.5 µg/kg) and esketamine (0.5 mg/kg)over 10 min before the induction of anesthesia, and then dexmedetomidine were infused at a rate of 0.4 µg/kg/h and 2 µg/kg/min until 20 min before the end of operation, respectively.; Patients received a bolus infusion of dexmedetomidine (0.5 µg/kg) and esketamine (0.5 mg/kg)over 10 min before the induction of anesthesia, and then dexmedetomidine were infused at a rate of 0.4 µg/kg/h and 4 µg/kg/min until 20 min before the end of operation, respectively.
Intervention MeSH terms: Dexmedetomidine; Esketamine
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary purpose: Treatment
Keywords: Dexmedetomidine; esketamine; pain; recovery quality